• Something wrong with this record ?

The role of glutathione redox imbalance in autism spectrum disorder: A review

G. Bjørklund, AA. Tinkov, B. Hosnedlová, R. Kizek, OP. Ajsuvakova, S. Chirumbolo, MG. Skalnaya, M. Peana, M. Dadar, A. El-Ansary, H. Qasem, JB. Adams, J. Aaseth, AV. Skalny

. 2020 ; 160 (-) : 149-162. [pub] 20200731

Language English Country United States

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc21019810

The role of glutathione in autism spectrum disorder (ASD) is emerging as a major topic, due to its role in the maintenance of the intracellular redox balance. Several studies have implicated glutathione redox imbalance as a leading factor in ASD, and both ASD and many other neurodevelopmental disorders involve low levels of reduced glutathione (GSH), high levels of oxidized glutathione (GSSG), and abnormalities in the expressions of glutathione-related enzymes in the blood or brain. Glutathione metabolism, through its impact on redox environment or redox-independent mechanisms, interferes with multiple mechanisms involved in ASD pathogenesis. Glutathione-mediated regulation of glutamate receptors [e.g., N-methyl-d-aspartate (NMDA) receptor], as well as the role of glutamate as a substrate for glutathione synthesis, may be involved in the regulation of glutamate excitotoxicity. However, the interaction between glutathione and glutamate in the pathogenesis of brain diseases may vary from synergism to antagonism. Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation. Mitochondrial dysfunction, as well as neuronal apoptosis, may also provide a significant link between glutathione metabolism and ASD. Furthermore, it has been recently highlighted that glutathione can affect and modulate DNA methylation and epigenetics. Review analysis including research studies meeting the required criteria for analysis showed statistically significant differences between the plasma GSH and GSSG levels as well as GSH:GSSG ratio in autistic patients compared with healthy individuals (P = 0.0145, P = 0.0150 and P = 0.0202, respectively). Therefore, the existing data provide a strong background on the role of the glutathione system in ASD pathogenesis. Future research is necessary to investigate the role of glutathione redox signaling in ASD, which could potentially also lead to promising therapeutics.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019810
003      
CZ-PrNML
005      
20210830101422.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.freeradbiomed.2020.07.017 $2 doi
035    __
$a (PubMed)32745763
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bjørklund, Geir $u Council for Nutritional and Environmental Medicine (CONEM), Mo I Rana, Norway. Electronic address: bjorklund@conem.org
245    14
$a The role of glutathione redox imbalance in autism spectrum disorder: A review / $c G. Bjørklund, AA. Tinkov, B. Hosnedlová, R. Kizek, OP. Ajsuvakova, S. Chirumbolo, MG. Skalnaya, M. Peana, M. Dadar, A. El-Ansary, H. Qasem, JB. Adams, J. Aaseth, AV. Skalny
520    9_
$a The role of glutathione in autism spectrum disorder (ASD) is emerging as a major topic, due to its role in the maintenance of the intracellular redox balance. Several studies have implicated glutathione redox imbalance as a leading factor in ASD, and both ASD and many other neurodevelopmental disorders involve low levels of reduced glutathione (GSH), high levels of oxidized glutathione (GSSG), and abnormalities in the expressions of glutathione-related enzymes in the blood or brain. Glutathione metabolism, through its impact on redox environment or redox-independent mechanisms, interferes with multiple mechanisms involved in ASD pathogenesis. Glutathione-mediated regulation of glutamate receptors [e.g., N-methyl-d-aspartate (NMDA) receptor], as well as the role of glutamate as a substrate for glutathione synthesis, may be involved in the regulation of glutamate excitotoxicity. However, the interaction between glutathione and glutamate in the pathogenesis of brain diseases may vary from synergism to antagonism. Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation. Mitochondrial dysfunction, as well as neuronal apoptosis, may also provide a significant link between glutathione metabolism and ASD. Furthermore, it has been recently highlighted that glutathione can affect and modulate DNA methylation and epigenetics. Review analysis including research studies meeting the required criteria for analysis showed statistically significant differences between the plasma GSH and GSSG levels as well as GSH:GSSG ratio in autistic patients compared with healthy individuals (P = 0.0145, P = 0.0150 and P = 0.0202, respectively). Therefore, the existing data provide a strong background on the role of the glutathione system in ASD pathogenesis. Future research is necessary to investigate the role of glutathione redox signaling in ASD, which could potentially also lead to promising therapeutics.
650    12
$a poruchy autistického spektra $x genetika $7 D000067877
650    12
$a autistická porucha $7 D001321
650    _2
$a glutathion $x metabolismus $7 D005978
650    _2
$a glutathiondisulfid $x metabolismus $7 D019803
650    _2
$a lidé $7 D006801
650    _2
$a oxidace-redukce $7 D010084
650    _2
$a oxidační stres $7 D018384
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Tinkov, Alexey A $u IM Sechenov First Moscow State Medical University, Moscow, Russia; Yaroslavl State University, Yaroslavl, Russia; Federal Research Centre of Biological Systems, Agro-technologies of the Russian Academy of Sciences, Orenburg, Russia
700    1_
$a Hosnedlová, Božena $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic; CONEM Metallomics Nanomedicine Research Group (CMNRG), Brno, Czech Republic
700    1_
$a Kizek, Rene $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic; CONEM Metallomics Nanomedicine Research Group (CMNRG), Brno, Czech Republic; Faculty of Pharmacy with Division of Laboratory Medicine, Wroclaw Medical University, Wroclaw, Poland
700    1_
$a Ajsuvakova, Olga P $u IM Sechenov First Moscow State Medical University, Moscow, Russia; Yaroslavl State University, Yaroslavl, Russia; Federal Research Centre of Biological Systems, Agro-technologies of the Russian Academy of Sciences, Orenburg, Russia
700    1_
$a Chirumbolo, Salvatore $u Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy; CONEM Scientific Secretary, Verona, Italy
700    1_
$a Skalnaya, Margarita G $u IM Sechenov First Moscow State Medical University, Moscow, Russia; Federal Research Centre of Biological Systems, Agro-technologies of the Russian Academy of Sciences, Orenburg, Russia
700    1_
$a Peana, Massimiliano $u Department of Chemistry and Pharmacy, University of Sassari, Italy
700    1_
$a Dadar, Maryam $u Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran
700    1_
$a El-Ansary, Afaf $u Medicinal Chemistry Department, King Saud University, Riyadh, Saudi Arabia; Autism Research and Treatment Center, Riyadh, Saudi Arabia; CONEM Saudi Autism Research Group, King Saud University, Riyadh, Saudi Arabia
700    1_
$a Qasem, Hanan $u Autism Research and Treatment Center, Riyadh, Saudi Arabia; CONEM Saudi Autism Research Group, King Saud University, Riyadh, Saudi Arabia
700    1_
$a Adams, James B $u School for Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, AZ, USA
700    1_
$a Aaseth, Jan $u Research Department, Innlandet Hospital Trust, Brumunddal, Norway
700    1_
$a Skalny, Anatoly V $u IM Sechenov First Moscow State Medical University, Moscow, Russia; Federal Research Centre of Biological Systems, Agro-technologies of the Russian Academy of Sciences, Orenburg, Russia
773    0_
$w MED00001857 $t Free radical biology & medicine $x 1873-4596 $g Roč. 160, č. - (2020), s. 149-162
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32745763 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101422 $b ABA008
999    __
$a ok $b bmc $g 1690592 $s 1140256
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 160 $c - $d 149-162 $e 20200731 $i 1873-4596 $m Free radical biology & medicine $n Free Radic Biol Med $x MED00001857
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options